Dihexa Peptide Research & Scientific Overview

Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Limitations | Lead Researcher | References

Dihexa Molecular Structure & Chemical Properties

Dihexa peptide(developmental code PNB-0408) is a small, orally active peptidomimetic derived from the angiotensin IV (Ang IV) fragment of the brain renin-angiotensin system. It was engineered at Washington State University to overcome the two pharmacokinetic weaknesses of native Ang IV: rapid enzymatic degradation and poor penetration of the blood-brain barrier. Through N-terminal hexanoylation and a C-terminal 6-aminohexanoic amide extension, dihexa gained substantial metabolic stability and lipophilicity, allowing oral activity and central nervous system exposure that are unusual for a peptide-derived molecule. These properties have made it one of the more intensely studied experimental compounds in preclinical cognitive and synaptic-plasticity research.

Chemical Structure

[IMAGE PLACEHOLDER] Insert 2D chemical structure image here Image URL: https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=129010512&t=l Alt text: Dihexa (PNB-0408) 2D molecular structure diagram Source credit: PubChem Position: Center-aligned below heading

2D molecular structure (Source: PubChem)

Technical Specifications

Structurally, dihexa retains the Tyr-Ile core of its parent scaffold while replacing peptidase-sensitive bonds with non-natural linkages, which accounts for its extended stability relative to Ang IV.

Dihexa Peptide Mechanism of Action

Dihexa’s proposed primary mechanism is potentiation of the hepatocyte growth factor (HGF) and its receptor c-Met (the product of the MET proto-oncogene). Rather than binding c-Met directly, dihexa is reported to bind HGF and facilitate its activity, enhancing c-Met phosphorylation and downstream signaling in the presence of subthreshold HGF concentrations [8]. Importantly, the two studies that first established this mechanism have since been retracted (see Research Limitations), so the HGF/c-Met model should be treated as a proposed rather than settled mechanism.

Primary Cellular Pathways

HGF/c-Met Potentiation

The originating work reported that dihexa binds HGF with high affinity and, together with its parent compound Nle1-Ang IV, augments HGF-dependent c-Met phosphorylation and cell scattering [8]. This activity was described as dependent on an intact HGF/c-Met axis, because HGF antagonists and c-Met knockdown blocked the observed effects [8]. Independent work in a sensory-cell model later reproduced HGF-dependence for dihexa’s protective activity [9], providing some external support for the pathway even after the original mechanistic papers were retracted.

PI3K/Akt and MAPK/ERK Signaling

Downstream of c-Met, dihexa has been associated with activation of the PI3K/Akt and MAPK/ERK cascades:

• An independent study in an Alzheimer’s disease mouse model reported PI3K/Akt pathway involvement in dihexa’s procognitive effects [13]
• These cascades are canonical mediators of neuronal survival and synaptic protein expression
• Reported effects include upregulation of synaptic markers such as synaptophysin [13]

Synaptogenesis and Dendritic Spine Formation

Across in vitro and rodent studies, angiotensin IV analogs including dihexa have been linked to hippocampal spinogenesis and synaptogenesis similar to that produced by HGF itself [4,8]. A frequently repeated claim that dihexa is roughly seven orders of magnitude more potent than brain-derived neurotrophic factor (BDNF) originates from this compromised body of work and should be interpreted with considerable caution.

Relationship to the Brain Renin-Angiotensin System

Dihexa’s lineage traces to Ang IV, a component of the brain renin-angiotensin system with documented effects on long-term potentiation and memory in rodents [1,2,5]. This background motivated the medicinal-chemistry program that produced dihexa as a stabilized, brain-penetrant analog [5].

[CALLOUT BOX – Highlighted] Key Mechanistic Insight: Dihexa’s proposed HGF/c-Met mechanism is biologically plausible and partially supported by independent work, but the two foundational biochemistry papers that defined it were retracted in 2025. The mechanism should be presented as a proposed model, not a validated one. [END CALLOUT BOX]

Dihexa Peptide Research Applications & Key Findings

Cognitive Research in Rodent Models

Preclinical investigations have examined dihexa and related Ang IV analogs in rodent models of cognitive deficit:

• Scopolamine-induced impairment: stabilized Ang IV analogs restored spatial-learning performance in rats [4,7]
• Aged-rat models: improved performance on memory-related tasks was reported for this compound class [7]
• Behavioral paradigms: findings were assessed using the Morris water maze, passive avoidance, and object-recognition tasks [4,7]

Alzheimer’s Disease Models

An independent group (outside the originating laboratory) evaluated dihexa in six-month-old APP/PS1 transgenic mice, a genetic model of amyloid pathology [13]. Over three months of intragastric administration, the study reported:

• Reduced escape latency and increased platform crossings in water-maze testing [13]
• Preserved neuronal density and increased synaptophysin expression [13]
• Reduced markers of glial activation and neuroinflammation [13]

Because this replication came from a separate research group, it is an important data point for the compound’s preclinical profile.

In Vitro Synaptogenesis

Cell-culture studies in hippocampal neurons characterized dihexa’s effects on dendritic spine morphology and synaptic density, forming the cellular basis for the synaptogenesis hypothesis [4]. These assays established the picomolar activity range frequently cited in the literature, though the strongest potency comparisons derive from now-retracted reports.

Sensory Hair Cell Protection

In a larval zebrafish lateral-line model, dihexa reduced aminoglycoside-induced hair cell death, an effect blocked by an HGF antagonist and consistent with HGF/c-Met-mediated protection [9]. Lateral-line hair cells are structurally and functionally comparable to mammalian inner-ear hair cells, making this a useful mechanistic model.

[CALLOUT BOX – Highlighted] Critical Research Limitation: Dihexa has NO completed, published human clinical trials. All efficacy data derive from rodent, zebrafish, and cell-culture studies, and several key mechanistic publications have been retracted. Human safety, dosing, and efficacy remain unestablished. [END CALLOUT BOX]

Dihexa Pharmacokinetics & Metabolism

Absorption & Distribution

Dihexa is notable among peptide-derived compounds for oral activity and blood-brain barrier permeability, both attributed to its increased lipophilicity and metabolic stability [4,5]:

• Oral administration produces central nervous system exposure in rodent studies [4]
• Enhanced hydrophobicity supports passive diffusion across the blood-brain barrier [5]
• The parent compound Nle1-Ang IV, by contrast, is rapidly degraded and poorly brain-penetrant [3]

Metabolism & Elimination

In rat pharmacokinetic characterization, dihexa demonstrated an unusually long circulating half-life for a molecule of its size [4]:

• Serum half-life of approximately 12.7 days following intravenous administration [4]
• Approximately 8.8 days following intraperitoneal administration [4]
• Low in vitro intrinsic clearance and a prolonged microsomal half-life, indicating minimal Phase I metabolism [4]

Some vendor materials cite a much shorter plasma half-life; the extended figures above come from the peer-reviewed primary characterization and should be preferred, while noting that the full metabolic pathway remains incompletely defined.

Excretion Pathways

Detailed excretion data for dihexa are limited:

• Elimination routes and metabolite identities are not fully characterized in the published literature
• The disconnect between a long measured half-life and the compound’s designed metabolic stability highlights a need for further quantitative pharmacokinetic study
• No comprehensive human pharmacokinetic data have been published [12]

Dihexa Research Protocols & Administration

Dosing in Published Research

Reported experimental doses vary by species, model, and route:

• Rat cognitive studies: approximately 0.1 to 2 mg/kg in scopolamine and aged-rat paradigms [4,7]
• APP/PS1 mouse studies: 1.44 and 2.88 mg/kg per day intragastrically over three months [13]
• In vitro assays: picomolar to micromolar concentrations depending on endpoint [4,9]

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to differences in metabolism, pharmacokinetics, receptor expression, and peptide degradation rates. Species-specific factors significantly influence both efficacy and safety profiles.

Administration Routes in Research

• Oral/intragastric – used in rodent cognition and Alzheimer’s-model studies [4,13]
• Intraperitoneal injection – used in pharmacokinetic and behavioral studies [4,13]
• Intravenous injection – used primarily for pharmacokinetic characterization [4]
• In vitro application – used in neuronal culture and zebrafish models [4,9]

Common Model Organisms

• Rats – primary rodent model for cognition studies (scopolamine and aged models) [4,7]
• Mice – APP/PS1 transgenic Alzheimer’s disease model [13]
• Zebrafish – larval lateral-line hair cell model [9]
• Cell culture – hippocampal neurons and HGF/c-Met signaling assays [4,8]

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite substantial preclinical interest, dihexa faces serious translational and evidentiary limitations that constrain its research utility.

Lack of Human Clinical Data

• No completed, published human clinical trials exist for dihexa itself [12]
• No published human pharmacokinetic, safety, or efficacy data [12]
• A structurally related subcutaneous prodrug (fosgonimeton/ATH-1017) was developed separately and studied in clinical programs; it is a distinct compound and does not establish dihexa’s own human profile

Research Integrity Concerns

A significant and unusual limitation for this compound is the retraction of foundational papers:

• Two central mechanistic papers (2012 and 2014) were formally retracted in 2025 following a Washington State University investigation that found figure manipulation in work co-authored by a former graduate student [6,8]
• A 2013 pharmacokinetic and cognition paper carries a 2021 Expression of Concern [7]
• These actions weaken the direct evidence linking dihexa’s effects specifically to HGF/c-Met activation, and widely repeated potency claims trace to the affected literature

Mechanistic Understanding Gaps

• The HGF/c-Met mechanism is proposed but not definitively validated following the retractions [8]
• Contribution of parent compound versus active metabolites is not established
• Quantitative excretion and metabolism data are incomplete [4]

Long-Term Safety Considerations

• Chronic-use effects are unstudied in humans and largely unstudied even in animals
• Because HGF/c-Met is a proliferative, pro-angiogenic pathway implicated in several cancers, potentiating it raises a theoretical oncogenic concern that remains uncharacterized [11]
• Reproductive, developmental, and drug-interaction profiles are not defined

Regulatory & Competitive Sport Status

FDA Position

• Dihexa is not approved by the FDA for any human indication
• Dihexa acetate was previously listed in Category 2 (“bulk drug substances that raise significant safety concerns”) on the FDA interim Section 503A bulks list
• In April 2026, the FDA removed dihexa acetate from Category 2 after the nomination was withdrawn; removal from Category 2 does not authorize compounding [14]
• The FDA has scheduled Pharmacy Compounding Advisory Committee review of dihexa acetate for possible 503A inclusion by early 2027; until any such action, it remains outside authorized compounding [14]

WADA Status

• Dihexa is not specifically enumerated by name on the WADA Prohibited List [15]
• As an agent that potentiates a growth-factor pathway, it plausibly falls within the S2.3 “Growth Factors and Growth Factor Modulators” language, and as a non-approved substance it is also plausibly captured under S0 (Non-Approved Substances), both prohibited at all times [15]
• Caveat: WADA has not published a position specifically addressing dihexa; athletes and researchers should verify current classification independently before relying on any interpretation

Research Classification: Dihexa is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

Lead Researcher Spotlight

Professor Joseph W. Harding, PhD

Department of Psychology / Integrative Physiology and Neuroscience Washington State University, Pullman, Washington, USA

Professor Joseph W. Harding, working with colleague Professor John W. Wright, led the long-running Washington State University program on the brain renin-angiotensin system that produced dihexa. Beginning in the 1990s with studies of angiotensin IV’s effects on memory, the group pursued a medicinal-chemistry campaign to create stabilized, brain-penetrant analogs, culminating in dihexa as its lead compound.

Key research focus areas included:

• Characterization of angiotensin IV and its analogs in learning and memory
• Development of metabolically stabilized, orally active peptidomimetics
• Investigation of the HGF/c-Met system as a target in neurodegeneration
• Preclinical cognition studies in rodent models

Readers should note that several of the laboratory’s key dihexa publications were subsequently retracted or flagged with an Expression of Concern (see Research Limitations), which is material context for evaluating the compound’s evidence base.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to dihexa research. Cenexa Labs has no affiliation with Professor Harding or Washington State University, and this information does not constitute an endorsement of any products or services.

References

1. Wright, J.W., & Harding, J.W. (2004). The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Progress in Neurobiology, 72(4), 263-293. PubMed
   
2. Wayner, M.J., Armstrong, D.L., Phelix, C.F., Wright, J.W., & Harding, J.W. (2001). Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides, 22(9), 1403-1414. PubMed
   
3. Yamamoto, B.J., Elias, P.D., Masino, J.A., Hudson, B.D., McCoy, A.T., Anderson, Z.J., Varnum, M.D., Sardinia, M.F., Wright, J.W., & Harding, J.W. (2010). The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. Journal of Pharmacology and Experimental Therapeutics, 333(1), 161-173. PubMed
   
4. Benoist, C.C., Wright, J.W., Zhu, M., Appleyard, S.M., Wayman, G.A., & Harding, J.W. (2011). Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. Journal of Pharmacology and Experimental Therapeutics, 339(1), 35-44. PubMed
   
5. Wright, J.W., & Harding, J.W. (2011). Brain renin-angiotensin – a new look at an old system. Progress in Neurobiology, 95(1), 49-67. PubMed
   
6. Kawas, L.H., McCoy, A.T., Yamamoto, B.J., Wright, J.W., & Harding, J.W. (2012). Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. Journal of Pharmacology and Experimental Therapeutics, 340(3), 539-548. (Retracted 2025.) PubMed
   
7. McCoy, A.T., Benoist, C.C., Wright, J.W., Kawas, L.H., Bule-Ghogare, J.M., Zhu, M., Appleyard, S.M., Wayman, G.A., & Harding, J.W. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics, 344(1), 141-154. (Expression of Concern, 2021.) PubMed
   
8. Benoist, C.C., Kawas, L.H., Zhu, M., Tyson, K.A., Stillmaker, L., Appleyard, S.M., Wright, J.W., Wayman, G.A., & Harding, J.W. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. Journal of Pharmacology and Experimental Therapeutics, 351(2), 390-402. (Retracted 2025.) PubMed
   
9. Uribe, P.M., Kawas, L.H., Harding, J.W., & Coffin, A.B. (2015). Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Frontiers in Cellular Neuroscience, 9, 3. PubMed
   
10. Wright, J.W., Kawas, L.H., & Harding, J.W. (2015). The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Progress in Neurobiology, 125, 26-46. PubMed
    
11. Wright, J.W., & Harding, J.W. (2015). The brain hepatocyte growth factor/c-Met receptor system: A new target for the treatment of Alzheimer’s disease. Journal of Alzheimer’s Disease, 45(4), 985-1000. PubMed
    
12. Ho, J.K., & Nation, D.A. (2018). Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neuroscience and Biobehavioral Reviews, 92, 209-225. PubMed
    
13. Sun, X., et al. (2021). AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sciences, 11(11), 1487. PubMed
    
14. U.S. Food and Drug Administration. (2026). Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act: Section 503A bulks list update and Pharmacy Compounding Advisory Committee notice. (FDA regulatory document; peer-reviewed publication not applicable.)
15. World Anti-Doping Agency. (2026). The 2026 Prohibited List: International Standard. (WADA regulatory document; peer-reviewed publication not applicable.)

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Dihexa is intended for laboratory research use only.